REGENON 25mg capsule me medication leaflet

A08AA03 amfepramone • Alimentary tract and metabolism | Antiobesity preparations, excl. diet products | Centrally acting antiobesity products

Amfepramone is a medication used as an adjunct in the treatment of obesity, particularly in patients who have not succeeded in losing weight through diet and exercise. It belongs to a class of drugs called anorectics and works by stimulating the central nervous system, reducing appetite, and increasing energy levels.

Amfepramone is taken orally, usually 30-60 minutes before meals, and treatment is recommended for short-term use, typically no more than a few weeks, to avoid the risk of dependence.

Side effects may include insomnia, nervousness, palpitations, increased blood pressure, and dry mouth. In rare cases, severe adverse reactions such as pulmonary hypertension or psychiatric disorders may occur.

Patients taking amfepramone should be closely monitored, and its use is contraindicated in individuals with cardiovascular conditions, severe hypertension, or a history of substance abuse. Additionally, the medication is not recommended during pregnancy or breastfeeding. Amfepramone can be a useful option for weight loss, but its use must be carefully supervised by a specialist physician.

General data about REGENON 25mg

Substance: amfepramone

Date of last drug list: 01-03-2023

Commercial code: W62884002

Concentration: 25mg

Pharmaceutical form: capsule me

Quantity: 60

Product type: original

Prescription restrictions: TAB3 - Medicines that are issued with a special prescription (psychotropic) in green color.

Marketing authorisation

Manufacturer: TEMMLER PHARMA GMBH - GERMANIA

Holder: TEMMLER PHARMA GMBH - GERMANIA

Number: 8699/2016/02

Shelf life: 2 years

Pharmaceutical forms available for amfepramone

Concentrations available for amfepramone

25mg, 60mg

Other substances similar to amfepramone